Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, "Laiko" General Hospital, 17 Agiou Thoma Street, 11527, Athens, Greece.
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, "Alexandra" General Hospital, Athens, Greece.
Clin J Gastroenterol. 2023 Apr;16(2):121-129. doi: 10.1007/s12328-022-01752-z. Epub 2023 Jan 2.
Portal hypertension (PH) is a major complication of liver cirrhosis, as it predisposes to the development of serious clinical manifestations such as ascites, hepatic encephalopathy and variceal bleeding, aggravating the prognosis of patients. Hepatic vein pressure gradient (HVPG) is considered the reference method for the estimation of the presence and severity of PH, but this procedure is available only in specialized centers. Alternatively, many non-invasive methods have been proposed in order to substitute HVPG. Among them, liver stiffness measurement (LSM) has been widely used, as it has been shown to correlate well with HVPG, though this relationship seems to weaken in values of HVPG higher than 12 mmHg, the threshold of serious complications development. Several studies supported the use of spleen stiffness measurement (SSM) instead of LSM, anticipating to a more adequate assessment of this advanced stage of PH. The aim of this paper is to critically appraise and summarize the literature about the role of SSM as a predictive tool of liver decompensation and prognosis, highlighting the strengths and the potential limitations of the studies published so far. EXPERT'S OPINION: The utility of SSM in ruling out high risk for bleeding varices in cirrhotic patients has been demonstrated, driving the Baveno VII consensus to encompass SSM in its last recommendations, though its use in patients with non-viral cirrhosis remains to be validated. We believe that in the near future, SSM alone or combined with other tests, will being used not only for sparing upper endoscopies, but also for predicting decompensation and prognosis in advanced compensated cirrhotic patients, regardless of liver disease's etiology. Herein, we present the data that support this consideration, pointing out these issues that should further be investigated in order to elucidate and intensify the value of SSM in the management of patients with liver cirrhosis.
门静脉高压症(PH)是肝硬化的主要并发症,因为它易导致腹水、肝性脑病和静脉曲张出血等严重临床症状的发展,从而加重患者的预后。肝静脉压力梯度(HVPG)被认为是估计 PH 存在和严重程度的参考方法,但该程序仅在专门中心提供。作为替代方案,已经提出了许多非侵入性方法来替代 HVPG。其中,肝硬度测量(LSM)已被广泛应用,因为它与 HVPG 相关性良好,尽管这种相关性在 HVPG 高于 12mmHg(严重并发症发展的阈值)时似乎减弱。几项研究支持使用脾脏硬度测量(SSM)代替 LSM,以更好地评估 PH 的这一晚期阶段。本文的目的是批判性地评价和总结有关 SSM 作为预测肝失代偿和预后的工具的文献,突出迄今为止发表的研究的优势和潜在局限性。专家意见:SSM 已被证明可用于排除肝硬化患者发生高危静脉曲张出血的可能性,这促使 Baveno VII 共识将 SSM 纳入其最新建议中,尽管其在非病毒性肝硬化患者中的应用仍有待验证。我们相信,在不久的将来,SSM 单独或与其他测试联合使用,不仅将用于避免进行上消化道内镜检查,而且还将用于预测晚期代偿性肝硬化患者的失代偿和预后,而不论其病因如何。在此,我们提出了支持这一观点的数据,并指出了这些问题,需要进一步研究以阐明和加强 SSM 在肝硬化患者管理中的价值。